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GVHD was 53% at 4-years. The overall response rate was 74%
(53% CR). Unrelated recipients had a trend for higher CR rate
than related recipients (Table). Overall, 45 patients are alive; 27 in
CR, 1 with minimal residual disease, 7 in PR, 2 with stable disease,
and 8 with relapse/progression. Thirty-seven pts died, 17 from
progression/relapse, 14 from infections  GVHD, 2 from cardiac
causes, 1 from metastatic lung cancer, 1 from cerebral stroke, 1
from rejection and aplasia, and one during open heart surgery for
a valve defect. Estimated 4-year rates of non-relapse mortality,
relapse, disease free, and overall survivals were 24%, 32%, 44%,
and 55% respectively. Among 31 surviving pts with the longest
follow up (24-86 months), 21 had developed chronic GVHD.
Fifteen of the 21 (median follow up of 49 months) had immuno-
suppression discontinued upon resolution of chronic GVHD while
6 (median follow up of 43 months) continued on immunosuppres-
sion. The median performance status (PS) of the 21 pts was 90%.
Nonmyeloablative HCT resulted in median survival of greater
than 4 years for pts with ﬂudarabine-refractory CLL. Pts with
longer follow up showed sustained remissions and continuing res-
olution of chronic GVHD with good performance status.
Table: Results stratiﬁed by donor type
Donor
Related
(n  52)
Unrelated
(n  30) p
Acute GVHD grade
II, III, and IV
39%, 14%,
and 2%
43%, 20%,
and 3%
0.19
Chronic extensive
GVHD at 4-years
51% 56% 0.94
Pts off
immunosuppression
at 3 years after
chronic GVHD
29% 52% 0.16
Pts alive and off
immunosuppression
at 4 years
29% 70%*
CR rate at 4-years 47% 63% 0.07
Relapse/progression
at 4-years
33% 31% 0.45
Surviving pts 13 CR, 1
MRD, 6
PR, 2
stable,
and 4
progression
14 CR, 1
PR, 2
progression,
and 2
relapse
Day-100 non-relapse
mortality
8% 10% 0.97
4-year non-relapse
mortality
23% 24% 0.97
4-year relapse-related
mortality
27% 12% 0.35
4-year disease-free
survival
43% 45% 0.59
4-year overall survival 50% 64% 0.62
*This is a temporary spike at exactly 4.0 years. The prevalence at
3.9 and 4.1 years is 53%. MRD indicates minimal residual
disease.
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REDUCED-INTENSITY STEM CELL TRANSPLANTATION FOR HIGH-RISK
ACUTE LYMPHOBLASTIC LEUKEMIA
Stein, A.1, O’Donnell, M.1, Snyder, D.1, Parker, P.1, Nademanee, A.1,
Falk, P.2, Kogut, N.2, Rosenthal, J.1, Palmer, J.1, Tsai, N.1,
Forman, S.1 1City of Hope National Medical Center, Duarte, CA;
2Kaiser Permanente Bone Marrow Transplant Program, Duarte, CA.
Reduced-intensity allogeneic stem cell transplantation (SCT) re-
lies mainly on graft versus leukemia (GVL) for its efﬁcacy; is
increasingly being used for treatment of hematological malignan-
cies. The role of GVL is less deﬁned in transplantation for acute
lymphoblastic leukemia (ALL). We report the experience of 21
ALL patients who were treated with ﬂudarabine 25mg/m2 daily for
5 days and melphalan 140 mg/m2 followed by Allo-SCT between
5/7/02 and 5/31/06. The indications for the reduced-intensity
regimen were: 1) previous Allo-SCT 5(24%), 2) 50 years 7(33%)
and 3) decreased organ function 9(43%). The patient/treatment
characteristics are: median age 46 years (6-68), remission status at
Allo-SCT: 1CR 10(48%), 1RL 3(14%), 2CR 4(19%) and 3CR
4(19%), Ph ALL 11(52%), donor type: match sibling 7(33%),
matched unrelated 14(67%), stem cell source: primed peripheral
stem cells 20(95%) and cord blood-double 1(5%), graft versus host
disease (GVHD) prophylaxis: cyclosporine(CSA)/methotrex-
ate(MTX) 4(19%), CSA/Mycophenylate(MMF) 9(43%), CSA/
ATG 1(5%) and CSA/MMF/MTX 1(5%). Six (28%) patients
received tacrolimus and sirolimus. With a median follow-up for
alive patients 17.0 months (range: 2.7-47.2), the one-year cumula-
tive probability of overall survival, disease-free survival and relapse
rate were 77.4% (95%CI: 57.2, 88.9), 70.9% (95%CI: 52.0, 83.4)
and 7.7% (95%CI: 1.3, 38.7) respectively. Incidence of acute
GVHD was 50% for grade II-IV and 15% for grade III-IV. Of the
patients evaluable for chronic GVHD, 11% developed limited
chronic GVHD and 33% developed extensive chronic GVHD.
The 100 day non-relapse mortality was 10%. The results of this
study show that RI Allo-SCT using ﬂudarabine/melphalan based
conditioning is a potential therapeutic approach for patients with
high-risk ALL who are not eligible for full intensity transplant.
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Background-purpose: The use of reduced intensity conditioning
regimen (RIC) may reduce non-relapse mortality (NRM) and allow
long term disease free survival (DFS) and overall survival (OS)
through graft versus leukemia (GVL) effect in patients considered not
eligible for convenitonal allogeneic stem cell transplantation (Allo-
SCT). In this multicenter, prospective study we report our experience
wit RIC regimen based on ﬂudarabine and busulfan. Patients and
methods: We included all 93 consecutive patients with AML and
MDS who underwent ﬂudarabine-busulphan RIC-Allo-SCT from an
HLA identical sibling, in 6 Spanish centers since 1998 to 2005.
Diagnoses were acute myeloid leukemia (AML) (n59) or myelodis-
plastic syndrome (MDS) (n34), median time from diagnostic was 6
(range 1-150) months. Median age was 58 (range 21-70) years. Follow
up for survivors was 43 months (3-89). Conditioning regimen con-
sisted of ﬂudarabine 150 mg/m2 and busulfan 8-10 mg/kg. Graft
versus host disease prophylaxis consisted of cyclosporin A and a short
course of methotrexate or mycofenolate mofetil. Results: These pa-
tients received a RIC regimen for advanced age /-comorbidities
(83%) previous SCT/- advanced age (9%) or active infection, poor
PS, or other comorbidities (8%). 56% of patients showed very high
risk disease (high risk karyotype, refractory disease or high risk IPSS).
Median time to neutrophil and platelet recovery was on day 17
(range7-27) and 11 (range 0-59) days respectively. Thirty three pa-
tients developed acute GVHD for a Cumulative Incidence (Cum Inc)
of 33% (95%CI 25-44) and 53 out of 77 evaluable patients developed
chronic GVHD for a Cum Inc of 54% (95% CI 44-65%). The
100-day and 1-year Cum Inc NRM was 8% and 17% respectively.
The 4 Years Relapse Cum Inc was 37% (95% CI 28-50%). The
4-years DFS was 43% (33-53%) for the whole group. The 4-year
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probability of OS was 45% (95% CI 33-57%) for the whole group.
OS for AML and MDS was 42% (95% CI 28-56%) and 49% (95%
CI 31-76%) (P0.4). In multivariate analyses, the factors associated
with worse OS were: More than 5% blast at SCT (HR 2.1 95% CI
1.1-4.2; P0.03) and the absence of chronic GVHD (HR 4.7, 95%
CI 2.3-9.5; P0.001) Conclusion: Our results supports the use of
RIC Allo-SCT as a curative option for those patients with high risk
NRM for conventional allo-SCT but who can beneﬁt from GVL
effect.
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Busulfan-based conditioning therapy is used for hematologic
malignancies prior to hematopoietic stem cell transplantation
(HSCT). A major obstacle to successful HSCT is post-transplant
recurrence of the disease. We hypothesize that a) inherent genet-
ically determined factors in the leukemic cell population have a
major contributory role in such treatment failure, and b) leukemic
cell gene expression proﬁling can be used to dissect factors that
contribute to cellular busulfan (Bu) resistance. Two Bu-resistant
myeloid leukemia cell lines were established through intermittent
exposure to gradually increasing Bu concentrations. The cells were
characterized and analyzed by microarray and real time PCR tech-
niques to identify genes that were differentially expressed in Bu
resistant (KBM7/B5-Bu2506 and KBM3-Bu2506) and parental
sensitive cells. The resistant cell lines are 4-5 fold more resistant
than their respective parental lines and evade Bu-mediated G2-
arrest and apoptosis, which is consistent with up-regulation of
anti-apoptotic genes including BCL-XL, BAG3, BCL2, BCL2A1,
and BCL2L10 and down-regulation of pro-apoptotic genes includ-
ing BID, BAX, BNIP3, BCL2L11, BIK, LTBR and TNFSF7. Expo-
sure to Bu did not activate caspases in the Bu resistant cells. This
is in contrast to what was seen in the parental drug-sensitive lines,
where Bu-induced apoptosis was mediated through activation of
caspases and additional hitherto unidentiﬁed mechanisms. Inhibi-
tion of caspases by Z-VAD-FMK completely inactivated PARP1
cleavage and reduced apoptosis by 50%. The Bu resistance of
Bu2506 cells may include up-regulation of the HSP90 protein.
Inhibition of HSP90 with geldanamycin made Bu2506 cells signif-
icantly more sensitive to Bu. The signiﬁcance of our observations
was conﬁrmed in cell samples derived from AML patients with
“chemotherapy refractory” AML who rapidly had failed allogeneic
stem cell transplantation following a high-dose Bu-based condi-
tioning program, as compared with leukemic cell gene proﬁles
from patients who after HSCT have remained in remission for
more than one year. We conclude that apoptotic signaling mech-
anisms and HSP90 expression may have important clinical roles in
treatment (i.e. allo-HSCT) failure after high-dose Bu-based con-
ditioning therapy and point to a potential beneﬁt for investigating
apoptosis altering small molecules together with alkylating agents
in this setting. (Supported by NIH grant P01 CA055164).
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